FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Schlenk

Research Profile

Disorders

Procedures

Physiology

Mutation

Concepts & Ideas

Chemicals & Drugs

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
Lars Bullinger; Hartmut Döhner; Konstanze Döhner; Marlies Götz; Susanne Hofmann; Annika C Russ; Richard F Schlenk; Michael Schmitt; Vanessa Schneider; Lu Zhang; Anna Babiak; Ursula Botzenhardt; Jochen Greiner
PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation--A Possible Target for ATRA Response in AML without t(15;17).
Richard F Schlenk; Konstanze Döhner; Hartmut Döhner
[Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
Frank G Rücker; A C Russ; Brigitte Schlegelberger; Richard F Schlenk; Thorsten Zenz; U Botzenhardt; S Cocciardi; Hartmut Döhner; Konstanze Döhner; Stefan Fröhling; Arnold Ganser; H Kett; Jürgen Krauter; C Langer; Peter Lichter; Lars Bullinger
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Schlenk (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lars Bullinger; Hartmut Döhner; Konstanze Döhner; Marlies Götz; Susanne Hofmann; Annika C Russ; Richard F Schlenk; Michael Schmitt; Vanessa Schneider; Lu Zhang; Anna Babiak; Ursula Botzenhardt; Jochen Greiner
PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation--A Possible Target for ATRA Response in AML without t(15;17).
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(9):2562-71.
2013: Richard F Schlenk; Konstanze Döhner; Hartmut Döhner
[Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
Der Internist 2013;54(2):171-8.
2013: Frank G Rücker; A C Russ; Brigitte Schlegelberger; Richard F Schlenk; Thorsten Zenz; U Botzenhardt; S Cocciardi; Hartmut Döhner; Konstanze Döhner; Stefan Fröhling; Arnold Ganser; H Kett; Jürgen Krauter; C Langer; Peter Lichter; Lars Bullinger
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
Leukemia 2013;27(2):353-61.
2013: Peter Paschka; Mark Ringhoffer; Mathias Rummel; Helmut R Salih; Brigitte Schlegelberger; Richard F Schlenk; Daniela Späth; Marie von Lilienfeld-Toal; Mohammed Wattad; Hartmut Döhner; Juan Du; Verena I Gaidzik; Arnold Ganser; K Götze; Gerhard Held; Heinz-August Horst; Sabine Kayser; Heinz Kirchen; Claus-Henning Köhne; Jürgen Krauter; Andrea Kündgen; Michael Lübbert; Lars Bullinger; Andrea Corbacioglu; Konstanze Döhner
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Blood 2013;121(1):170-7.
2013: Stefan Gröschel; Marije Havermans; Jürgen Krauter; Michael W M Kühn; Bob Löwenberg; Michael Lübbert; Gert J Ossenkoppele; Thomas Pabst; Veronika Rockova; Brigitte Schlegelberger; Richard F Schlenk; Ingo G H Schmidt-Wolf; Gerrit J Schuurhuis; Veronica Teleanu; Peter J M Valk; Peter Vandenberghe; Edo Vellenga; Leo F Verdonck; Gregor Verhoef; Hartmut Döhner; Konstanze Döhner; Karina Eiwen; Jan Engelmann; Claudia Erpelinck; Arnold Ganser; Ulrich Germing; Mario Bargetzi; Berna Beverloo; Ruud Delwel
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(1):95-103.
2012: Anna Dolnik; Julia C Engelmann; Tamara Fries; Verena I Gaidzik; Berit Haldemann; Sabine Kayser; Sabine Kelkenberg-Schade; Jan Krönke; Michael W M Kühn; Claudio Lottaz; Julian Mauch; Peter Paschka; Frank G Rücker; Maren Scharfenberger-Schmeer; Richard F Schlenk; Stephan Wolf; Hartmut Döhner; Konstanze Döhner; Lars Bullinger
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.
Blood 2012;120(18):e83-92.
2012: Thomas Büchner; Hartmut Döhner; Konstanze Döhner; Gerhard Ehninger; Arnold Ganser; Joerg Hasford; Rüdiger Hehlmann; Gerhard Heil; Achim Heinecke; Wolfgang Hiddemann; Dieter Hoelzer; Verena S Hoffmann; Rainer Krahl; Michael Kramer; Jürgen Krauter; Utz Krug; Dietger W Niederwieser; Maria Cristina Sauerland; Markus Schaich; Richard F Schlenk; Sebastian Scholl; Daniela Späth; Wolfgang E Berdel; Markus Pfirrmann
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(29):3604-10.
2012: Jan J Cornelissen; Alois Gratwohl; Gunnar Juliusson; Bob Löwenberg; Mohamad Mohty; Dietger Niederwieser; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Richard F Schlenk; Jorge Sierra; Gerard Socie; Martin Bornhäuser; Gert J Ossenkoppele
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.
Nature reviews. Clinical oncology 2012;9(10):579-90.
2012: Gabriele Nagel; Randi Selmer; Daniela Späth; Pär Stattin; Tanja Stocks; Hanno Ulmer; Tone Bjørge; Hans Concin; Anders Engeland; Christel Häggström; Göran Hallmans; Anette Hjartåker; Håkan Jonsson; Björn Lindkvist; Jonas Manjer; Richard F Schlenk
Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can).
Annals of hematology 2012;91(10):1519-31.
2012: Verena I Gaidzik; Ulrich Germing; K Götze; Detlef Haase; Marianne Habdank; Gerhard Held; Heinz-August Horst; Claus-Henning Köhne; Peter Paschka; Richard F Schlenk; Daniela Späth; Marie von Lilienfeld-Toal; Martin Bentz; Lars Bullinger; Hartmut Döhner; Konstanze Döhner
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(12):1350-7.
2012: Michael W M Kühn; Jing Ma; Peter Paschka; Stanley Pounds; Asmaa Quessar; Ina Radtke; Raul Ribeiro; Jeffrey E Rubnitz; Richard F Schlenk; Sheila A Shurtleff; Xiaoping Su; Jennifer Edelmann; Verena I Gaidzik; Arnold Ganser; Juliane Gohlke; Salil Goorha; Karlheinz Holzmann; Jürgen Krauter; Jan Krönke; Lars Bullinger; Jinjun Cheng; Hartmut Döhner; Konstanze Döhner; James R Downing
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.
Blood 2012;119(10):e67-75.
2012: Frank G Rücker; Brigitte Schlegelberger; Richard F Schlenk; Veronica Teleanu; Marie von Lilienfeld-Toal; Thorsten Zenz; Lars Bullinger; Konstanze Döhner; Stefan Fröhling; Verena I Gaidzik; Arnold Ganser; Marianne Habdank; Gerhard Held; Karlheinz Holzmann; Sabine Kayser; Helena Kett; Jürgen Krauter; Carla-Maria Kugler; Peter Lichter; Michael Lübbert; Peter Paschka; Hartmut Döhner
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Blood 2012;119(9):2114-21.
2012: Thomas Schroeder; Michael Stadler; Fabian Zohren; Friederike Braulke; Ingmar Bruns; Akos G Czibere; Roland Fenk; Norbert Gattermann; Rainer Haas; Detlef Haase; Sabine Kayser; Viola Klärner; Guido Kobbe; Nicolaus Kröger; Andrea Kuendgen; Uwe Platzbecker; Richard F Schlenk; Ulrich Germing
Therapy-related myeloid neoplasms following treatment with radioiodine.
Haematologica 2012;97(2):206-12.
2012: Sabine Kayser; Claus-Henning Köhne; Jürgen Krauter; Carina Morlok; David Nachbaur; Mathias Rummel; Brigitte Schlegelberger; Richard F Schlenk; Daniela Späth; Veronica Teleanu; Marie von Lilienfeld-Toal; Sibylla Wilhelm; Manuela Zucknick; Hartmut Döhner; Konstanze Döhner; Arnold Ganser; Ulrich Germing; Gudrun Göhring; K Götze; Gerhard Held; Heinz A Horst
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.
Blood 2012;119(2):551-8.
2011: Annika C Russ; Sandrine Sander; Richard F Schlenk; Marion Bauer; Hartmut Döhner; Konstanze Döhner; Karlheinz Holzmann; Hans A Kestler; Katharina M Lang; Sonja C Lück; Frank G Rücker; Lars Bullinger
Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
Haematologica 2011;96(12):1783-91.
2011: S C Lück; Peter Paschka; A C Russ; Richard F Schlenk; U Botzenhardt; Hartmut Döhner; Konstanze Döhner; Simone Fulda; Lars Bullinger
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups.
Leukemia 2011;25(11):1728-38.
2011: Marie-Luise Hütter; Richard F Schlenk
Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.
Expert opinion on biological therapy 2011;11(10):1369-80.
2011: Jan Krönke; Michael Lübbert; Hans-Günther Mergenthaler; David Nachbaur; Shiva Onken; Peter Paschka; Helmut R Salih; Brigitte Schlegelberger; Richard F Schlenk; Daniela Späth; Florian Tschürtz; Marie von Lilienfeld-Toal; Mohammed Wattad; Karina Eiwen; Verena I Gaidzik; Arnold Ganser; Ulrich Germing; Gudrun Göhring; Detlef Haase; Marianne Habdank; Gerhard Held; Kai-Ole Jensen; Thomas Kindler; Jürgen Krauter; Andrea Corbacioglu; Hartmut Döhner; Konstanze Döhner
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(19):2709-16.
2011: F Stegelmann; C Blersch; Lars Bullinger; Hartmut Döhner; Martin Griesshammer; S Kuhn; Peter Paschka; S Schauer; Richard F Schlenk; Konstanze Döhner
DNMT3A mutations in myeloproliferative neoplasms.
Leukemia 2011;25(7):1217-9.
2011: Matthias Stelljes; Carsten Müller-Tidow; Claudia Rossig; Richard F Schlenk; Gerda Silling; Wolfgang E Berdel; Andrea Corbacioglu; Hartmut Döhner; Konstanze Döhner; Karoline Ehlert; M C Frühwald; H Juergens; Joachim Kienast; Steffen Koschmieder
Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML.
Leukemia 2011;25(7):1209-10.
2011: Verena I Gaidzik; Lars Bullinger; Richard F Schlenk; Andreas S Zimmermann; Jürgen Röck; Peter Paschka; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Daniela Späth; Andrea Kündgen; Ingo G H Schmidt-Wolf; K Götze; David Nachbaur; Michael Pfreundschuh; Heinz A Horst; Hartmut Döhner; Konstanze Döhner
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(10):1364-72.
2011: Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
Blood 2011;117(8):2469-75.
2011: Sabine Kayser; Konstanze Döhner; Jürgen Krauter; Claus-Henning Köhne; Heinz A Horst; Gerhard Held; Marie von Lilienfeld-Toal; Sibylla Wilhelm; Andrea Kündgen; K Götze; Mathias Rummel; David Nachbaur; Brigitte Schlegelberger; Gudrun Göhring; Daniela Späth; Carina Morlok; Manuela Zucknick; Arnold Ganser; Hartmut Döhner; Richard F Schlenk
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.
Blood 2011;117(7):2137-45.
2011: Frank G Rücker; Lars Bullinger; Alexander Gribov; Martin Sill; Richard F Schlenk; Peter Lichter; Hartmut Döhner; Konstanze Döhner
Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML.
Genes, chromosomes & cancer 2011;50(1):51-8.
2010: Richard F Schlenk; Konstanze Döhner; Silja Mack; Michael Stoppel; Franz Király; K Götze; Frank Hartmann; Heinz A Horst; Elisabeth Koller; Andreas Petzer; Wolfgang Grimminger; Guido Kobbe; Axel Glasmacher; Hans Salwender; Heinz Kirchen; Detlef Haase; Stephan Kremers; Axel Matzdorff; Axel Benner; Hartmut Döhner
Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4642-8.
2010: Sanne Lugthart; Stefan Gröschel; Berna Beverloo; Sabine Kayser; Peter J M Valk; Shama Lydia van Zelderen-Bhola; Gert Jan Ossenkoppele; Edo Vellenga; Eva van den Berg-de Ruiter; Urs Schanz; Gregor Verhoef; Peter Vandenberghe; Augustin Ferrant; Claus-Henning Köhne; Michael Pfreundschuh; Heinz A Horst; Elisabeth Koller; Marie von Lilienfeld-Toal; Martin Bentz; Arnold Ganser; Brigitte Schlegelberger; Martine Jotterand; Jürgen Krauter; Thomas Pabst; Matthias Theobald; Richard F Schlenk; Ruud Delwel; Konstanze Döhner; Bob Löwenberg; Hartmut Döhner
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3890-8.
2010: Andrea Corbacioglu; Claudia Scholl; Richard F Schlenk; Karina Eiwen; Juan Du; Lars Bullinger; Stefan Fröhling; Peter Reimer; Mathias Rummel; Hans Günter Derigs; David Nachbaur; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(23):3724-9.
2010: Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; K Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(22):3636-43.
2010: Sonja C Lück; Annika C Russ; Juan Du; Verena Gaidzik; Richard F Schlenk; Jonathan R Pollack; Konstanze Döhner; Hartmut Döhner; Lars Bullinger
KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
British journal of haematology 2010;148(6):925-37.
2010: Lars Bullinger; J Krönke; C Schön; I Radtke; K Urlbauer; U Botzenhardt; V Gaidzik; A Carió; C Senger; Richard F Schlenk; J R Downing; K Holzmann; Konstanze Döhner; Hartmut Döhner
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis.
Leukemia 2010;24(2):438-49.
2010: Lars Bullinger; Mathias Ehrich; Konstanze Döhner; Richard F Schlenk; Hartmut Döhner; Matthew R Nelson; Dirk van den Boom
Quantitative DNA methylation predicts survival in adult acute myeloid leukemia.
Blood 2010;115(3):636-42.
2009: Sabine Kayser; Richard F Schlenk; Martina Correa Londono; Frank Breitenbuecher; Kerstin Wittke; Juan Du; Silja Groner; Daniela Späth; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Thomas Fischer; Konstanze Döhner
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
Blood 2009;114(12):2386-92.
2009: Stephan Stilgenbauer; Thorsten Zenz; Dirk Winkler; Andreas Bühler; Richard F Schlenk; Silja Groner; Raymonde Busch; Manfred Hensel; Ulrich Dührsen; Jürgen Finke; Peter Dreger; Ulrich Jäger; Eva Lengfelder; Karin Hohloch; Ulrike Söling; Rudolf Schlag; Michael Kneba; Michael Hallek; Hartmut Döhner
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):3994-4001.
2009: Verena Ingeborg Gaidzik; Richard F Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
Blood 2009;113(19):4505-11.
2009: Richard F Schlenk; Konstanze Döhner
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia.
Current opinion in hematology 2009;16(2):98-104.
2009: Richard F Schlenk; Konstanze Döhner; Michael Kneba; K Götze; Frank Hartmann; F del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.
Haematologica 2009;94(1):54-60.
2008: Maria Teresa Voso; Stefan Hohaus; Francesco Guidi; E Fabiani; Francesco D'Alò; S Groner; D Späth; K Doehner; Giuseppe Leone; H Doehner; Richard F Schlenk
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia.
Leukemia 2008;22(9):1685-91.
2008: Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
The New England journal of medicine 2008;358(18):1909-18.
2008: Lars Bullinger; Konstanze Döhner; Raphael Kranz; Christoph Stirner; Stefan Fröhling; Claudia Scholl; Young H Kim; Richard F Schlenk; Robert Tibshirani; Hartmut Döhner; Jonathan R Pollack
An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.
Blood 2008;111(9):4490-5.
2008: Richard F Schlenk; Marcelo C Pasquini; Waleska S Pérez; Mei-Jie Zhang; Jürgen Krauter; Joseph H Antin; Asad Bashey; Brian J Bolwell; Thomas Büchner; Jean-Yves Cahn; Mitchell S Cairo; Edward A Copelan; Corey Cutler; Hartmut Döhner; Robert Peter Gale; Osman Ilhan; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Richard T Maziarz; Philip L McCarthy; Stephen D Nimer; Jorge Sierra; Martin S Tallman; Daniel J Weisdorf; Mary M Horowitz; Arnold Ganser
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(2):187-96.
2008: Michael Schmitt; Anita Schmitt; Markus T Rojewski; Jinfei Chen; Krzysztof Giannopoulos; Fei Fei; Yingzhe Yu; Marlies Götz; Marta Heyduk; Gerd Ritter; Daniel E Speiser; Sacha Gnjatic; Philippe Guillaume; Mark Ringhoffer; Richard F Schlenk; Peter Liebisch; Donald Bunjes; Hiroshi Shiku; Hartmut Dohner; Jochen Greiner
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Blood 2008;111(3):1357-65.
2007: Michael Heuser; Bob Argiropoulos; Florian Kuchenbauer; Eric Yung; Jessica Piper; Stephen Fung; Richard F Schlenk; Konstanze Dohner; Tanja Hinrichsen; Cornelia Rudolph; Axel Schambach; Christopher Baum; Brigitte Schlegelberger; Hartmut Dohner; Arnold Ganser; R Keith Humphries
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML.
Blood 2007;110(5):1639-47.
2007: Lars Bullinger; Frank G Rücker; Stephan Kurz; Juan Du; Claudia Scholl; Sandrine Sander; Andrea Corbacioglu; Claudio Lottaz; Jürgen Krauter; Stefan Fröhling; Arnold Ganser; Richard F Schlenk; Konstanze Döhner; Jonathan R Pollack; Hartmut Döhner
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.
Blood 2007;110(4):1291-300.
2007: Markus Schaich; Richard F Schlenk; Haifa-Kathrin Al-Ali; Hartmut Döhner; Arnold Ganser; Gerhard Heil; Thomas Illmer; Rainer Krahl; Jürgen Krauter; Cristina Sauerland; Thomas Büchner; Gerhard Ehninger
Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
Haematologica 2007;92(6):763-70.
2007: Claudia Scholl; Dimple Bansal; Konstanze Döhner; Karina Eiwen; Brian J P Huntly; Benjamin H Lee; Frank G Rücker; Richard F Schlenk; Lars Bullinger; Hartmut Döhner; D Gary Gilliland; Stefan Fröhling
The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis.
The Journal of clinical investigation 2007;117(4):1037-48.
2006: Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.
Blood 2006;108(13):4109-17.
2006: Stefan Fröhling; Richard F Schlenk; Sabine Kayser; Martina Morhardt; Axel Benner; Konstanze Döhner; Hartmut Döhner
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
Blood 2006;108(10):3280-8.
2006: Konstanze Döhner; Juan Du; Andrea Corbacioglu; Claudia Scholl; Richard F Schlenk; Hartmut Döhner
JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia.
Haematologica 2006;91(11):1569-70.
2006: Thorsten Zenz; Matthias Ritgen; Peter Dreger; Alexander Kröber; Thomas F E Barth; Richard F Schlenk; Sebastian Böttcher; Michael Hallek; Michael Kneba; Donald Bunjes; Hartmut Döhner; Stephan Stilgenbauer
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
Blood 2006;108(6):2127-30.
2006: Frank G Rücker; Lars Bullinger; Carsten Schwaenen; Daniel B Lipka; Swen Wessendorf; Stefan Fröhling; Martin Bentz; Simone Miller; Claudia Scholl; Richard F Schlenk; Bernhard Radlwimmer; Hans A Kestler; Jonathan R Pollack; Peter Lichter; Konstanze Döhner; Hartmut Döhner
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(24):3887-94.
2006: Richard F Schlenk; Stefan Fröhling; Frank Hartmann; J Th Fischer; Axel Glasmacher; F del Valle; K Götze; Christoph Nerl; R Schoch; Hans Pralle; H G Mergenthaler; M Hensel; E Koller; H Kirchen; Axel C Matzdorff; Hans Salwender; H G Biedermann; Stephan Kremers; Detlef Haase; Axel Benner; Konstanze Döhner; Hartmut Döhner
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
Leukemia 2006;20(4):748-50.
2006: Alexander Kröber; Johannes Bloehdorn; Sebastian Hafner; Andreas Bühler; Till Seiler; Dirk Kienle; Dirk Winkler; Markus Bangerter; Richard F Schlenk; Axel Benner; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):969-75.
2006: Thorsten Zenz; Gerhard Glatting; Richard F Schlenk; Inga Buchmann; Hartmut Döhner; Sven N Reske; Donald Bunjes
Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
Haematologica 2006;91(2):285-6.
2006: Thorsten Zenz; Richard F Schlenk; Gerhard Glatting; Bernd Neumaier; Norbert M Blumstein; Inga Buchmann; Stephanie von Harsdorf; Mark Ringhoffer; Markus Wiesneth; Frieder Keller; Jörg Kotzerke; Erwin M Röttinger; Stephan Stilgenbauer; Hartmut Döhner; Sven N Reske; Donald Bunjes
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(2):278-86.
2006: Stefan Fröhling; Daniel B Lipka; Sabine Kayser; Claudia Scholl; Richard F Schlenk; Hartmut Döhner; D Gary Gilliland; Ross Levine; Konstanze Döhner
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.
Blood 2006;107(3):1242-3.
2006: Andrea Kuendgen; Mathias Schmid; Richard F Schlenk; Sabine Knipp; Barbara Hildebrandt; Christian Steidl; Ulrich Germing; Rainer Haas; Hartmut Dohner; Norbert Gattermann
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Cancer 2006;106(1):112-9.
2005: Claudia Scholl; Richard F Schlenk; Karina Eiwen; Hartmut Döhner; Stefan Fröhling; Konstanze Döhner
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Haematologica 2005;90(12):1626-34.
2005: Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
Blood 2005;106(12):3740-6.
2005: Richard F Schlenk; U Germing; Frank Hartmann; Axel Glasmacher; J Th Fischer; F del Valle y Fuentes; K Götze; Hans Pralle; Christoph Nerl; Hans Salwender; Wolfgang Grimminger; A Petzer; M Hensel; Axel Benner; L Zick; Konstanze Döhner; Stefan Fröhling; Hartmut Döhner
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Leukemia 2005;19(6):978-83.
2005: Stefan Fröhling; Richard F Schlenk; Jürgen Krauter; Christian Thiede; Gerhard Ehninger; Detlef Haase; Lana Harder; Sylvia Kreitmeier; Claudia Scholl; Michael A Caligiuri; Clara D Bloomfield; Hartmut Döhner; Konstanze Döhner
Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.
Genes, chromosomes & cancer 2005;42(4):427-32.
2005: Stefan Fröhling; Sabine Kayser; Cora Mayer; Simone Miller; Christa Wieland; Silvia Skelin; Richard F Schlenk; Hartmut Döhner; Konstanze Döhner
Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia.
Haematologica 2005;90(2):194-9.
2004: Richard F Schlenk; Stefan Fröhling; Frank Hartmann; J Th Fischer; Axel Glasmacher; F del Valle; Wolfgang Grimminger; K Götze; C Waterhouse; R Schoch; Hans Pralle; H G Mergenthaler; M Hensel; E Koller; H Kirchen; J Preiss; Hans Salwender; H G Biedermann; Stephan Kremers; F Griesinger; Axel Benner; B Addamo; Konstanze Döhner; Rainer Haas; Hartmut Döhner
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Leukemia 2004;18(11):1798-803.
2004: Matthias Ritgen; Stephan Stilgenbauer; Nils von neuhoff; Andreas Humpe; Monika Brüggemann; Christiane Pott; Thorsten Raff; Alexander Kröber; Donald Bunjes; Richard F Schlenk; Norbert Schmitz; Hartmut Döhner; Michael Kneba; Peter Dreger
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.
Blood 2004;104(8):2600-2.
2004: Richard F Schlenk; Axel Benner; Jürgen Krauter; Thomas Büchner; Cristina Sauerland; Gerhard Ehninger; Markus Schaich; B Mohr; Dietger Niederwieser; Rainer Krahl; Rita Pasold; Konstanze Döhner; Arnold Ganser; Hartmut Döhner; Gerhard Heil
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(18):3741-50.
2004: Mark Ringhoffer; Markus Wiesneth; Stephanie von Harsdorf; Richard F Schlenk; Anita Schmitt; Peter Reinhardt; Margit Moessner; Wolfgang Grimminger; Thomas Mertens; Sven N Reske; Hartmut Döhner; Donald Bunjes
CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients.
British journal of haematology 2004;126(4):527-35.
2004: Lars Bullinger; Konstanze Döhner; Eric Bair; Stefan Fröhling; Richard F Schlenk; Robert Tibshirani; Hartmut Döhner; Jonathan R Pollack
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
The New England journal of medicine 2004;350(16):1605-16.
2004: Stefan Fröhling; Richard F Schlenk; Ina Stolze; Jörg Bihlmayr; Axel Benner; Sylvia Kreitmeier; Karen Tobis; Hartmut Döhner; Konstanze Döhner
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):624-33.
2003: Konstanze Döhner; Karen Tobis; Tobias Bischof; Stefan Hein; Richard F Schlenk; Stefan Fröhling; Hartmut Döhner
Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM).
Blood 2003;102(10):3850; author reply 3850-1.
2003: Claudia Scholl; Heike Breitinger; Richard F Schlenk; Hartmut Döhner; Stefan Fröhling; Konstanze Döhner
Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
Genes, chromosomes & cancer 2003;38(3):274-80.
2003: Richard F Schlenk; Axel Benner; Frank Hartmann; F del Valle; C Weber; Hans Pralle; J Th Fischer; U Gunzer; Antonio Pezzutto; W Weber; Wolfgang Grimminger; J Preiss; M Hensel; Stefan Fröhling; Konstanze Döhner; Rainer Haas; Hartmut Döhner
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Leukemia 2003;17(8):1521-8.
2002: Stefan Fröhling; Richard F Schlenk; Jochen Breitruck; Axel Benner; Sylvia Kreitmeier; Karen Tobis; Hartmut Döhner; Konstanze Döhner
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
Blood 2002;100(13):4372-80.
2002: Konstanze Döhner; Karen Tobis; Regina Ulrich; Stefan Fröhling; Axel Benner; Richard F Schlenk; Hartmut Döhner
Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3254-61.
2002: Thomas F E Barth; Martin Bentz; Frank Leithäuser; Stephan Stilgenbauer; Reiner Siebert; Magdalena Schlotter; Richard F Schlenk; Hartmut Döhner; Peter Möller
Pathogenic complexity of gastric B-cell lymphoma.
Blood 2002;100(3):1095-6; author reply 1096-7.
2002: Stefan Fröhling; Silvia Skelin; Claudia Liebisch; Claudia Scholl; Richard F Schlenk; Hartmut Döhner; Konstanze Döhner
Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2480-5.
2002: Richard F Schlenk; Frank Hartmann; M Hensel; W Jung; R Weber-Nordt; A Gabler; Rainer Haas; A D Ho; Lorenz Trümper; Hartmut Döhner
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Leukemia 2002;16(4):581-6.
2001: Thomas F E Barth; Martin Bentz; Frank Leithäuser; Stephan Stilgenbauer; Reiner Siebert; Magdalena Schlotter; Richard F Schlenk; Hartmut Döhner; Peter Möller
Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract.
Genes, chromosomes & cancer 2001;31(4):316-25.
2001: Guido Marcucci; Michael A Caligiuri; Hartmut Döhner; Kellie J Archer; Richard F Schlenk; Konstanze Döhner; Eman Maghraby; Clara D Bloomfield
Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
Leukemia 2001;15(7):1072-80.
2001: A Seute; Hans-Peter Sinn; Richard F Schlenk; Robert Emig; Diethelm Wallwiener; Eva-Maria Grischke; Stefan Hohaus; Hartmut Döhner; Rainer Haas; Martin Bentz
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients.
International journal of cancer. Journal international du cancer 2001;93(1):80-4.
2000: Konstanze Döhner; Richard F Schlenk; B A van der Reijden; H Döhner
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Leukemia 2000;14(6):1154.
2000: Maria Teresa Voso; S Martin; Stefan Hohaus; A Abdallah; Richard F Schlenk; Anthony Ho; Rainer Haas
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
Bone marrow transplantation 2000;25(9):957-64.
1999: Stefan Hohaus; L Funk; S Martin; Richard F Schlenk; A Abdallah; U Hahn; Gerlinde Egerer; Hartmut Goldschmidt; Andreas Schneeweiss; Nicos Fersis; S Kaul; Diethelm Wallwiener; Gunther Bastert; Rainer Haas
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
British journal of cancer 1999;79(9-10):1500-7.
1999: Maria Teresa Voso; Stefan Hohaus; Marion Moos; M Pförsich; Friedrich W Cremer; Richard F Schlenk; S Martin; Ute Hegenbart; Hartmut Goldschmidt; Rainer Haas
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content.
British journal of haematology 1999;104(2):382-91.
1999: Stefan Hohaus; S Martin; Andreas Schneeweiss; Maria Teresa Voso; Richard F Schlenk; Diethelm Wallwiener; Gunther Bastert; Rainer Haas
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer.
Cancer chemotherapy and pharmacology 1999;44 Suppl():S13-7.
1997: Richard F Schlenk; Hartmut Döhner; M Pförsich; Axel Benner; K Fischer; Frank Hartmann; J Th Fischer; W Weber; U Gunzer; Hans Pralle; Rainer Haas
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone.
British journal of haematology 1997;99(2):386-93.
1996: K Fischer; Claudia Scholl; J Sàlat; Stefan Fröhling; Richard F Schlenk; Martin Bentz; Stephan Stilgenbauer; Peter Lichter; Hartmut Döhner
Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia.
Blood 1996;88(10):3962-71.
1995: Hartmut Döhner; K Fischer; Martin Bentz; K Hansen; Axel Benner; G Cabot; D Diehl; Richard F Schlenk; J Coy; Stephan Stilgenbauer
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
Blood 1995;85(6):1580-9.
1992: Andreas Ruf; Richard F Schlenk; A Maras; E Morgenstern; H Patscheke
Contact-induced neutrophil activation by platelets in human cell suspensions and whole blood.
Blood 1992;80(5):1238-46.